TrippBio is founded on the research of Ralph Tripp, Ph.D. the Georgia Research Alliance chair and Professor at the University of Georgia.
Dr. Moti N. Ramgopal of Midway Immunology and Research Center launched the investigator-initiated study to assess the efficacy of TD213 in treating patients with confirmed mild - moderate COVD-19 infections.
Ramgopal announced the final patient was enrolled in this proof of concept study and all participants are progressing through the protocol designated testing and follow-up visits. Recognized as one of the leading infectious disease doctors in the United States, Dr. Ramgopal's research center is committed to all the health needs of the patient.
TrippBio is a SpinUp Campus company. SpinUp Campus focuses on connecting university scientists with public investors to transform groundbreaking research into viable businesses that can change the world.
TrippBio said it needs the support of the worldwide community to continue into the next phase of testing and will use the capital from ongoing equity crowdfunding to extend clinical trials needed to seek global regulatory approval and commercialization of TD213.
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid
Hoth Therapeutics regains Nasdaq compliance
TME Pharma and SERI partner to advance NOX-E36 in ophthalmology through option framework agreement
Merry Life launches TML-6 global Phase II trial for Alzheimer's Disease
Galderma's nemolizumab recommended for NHS funding in England and Wales for atopic dermatitis
UCB announces BIMZELX (bimekizumab-bkzx) three-year data at EULAR 2025
Vivoryon Therapeutics presents positive meta-analysis data for varoglutamstat
Sanofi's rilzabrutinib granted US orphan drug designation for sickle cell disease
Sanofi to acquire Blueprint Medicines in USD9.5bn rare disease deal
Genentech reports sustained two-year benefits from fenebrutinib in relapsing multiple sclerosis
RemeGen secures approval in China for Telitacicept in treating generalised myasthenia gravis
TME Pharma announces extension of financial visibility to May 2026